Previous 10 | Next 10 |
Delcath Systems Announces an Independent Investigator Presentation at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Annual Meeting PR Newswire A Retrospective Comparative Study of SIRT and CS-PHP for Liver Targeted Therapy of Patients with Metast...
2023-08-16 12:24:29 ET Summary Delcath Systems received FDA approval for its HEPZATO Kit device as a treatment for liver-dominant eye cancer, resulting in the stock price surging over $7.00. Concerns arise over the company's history of dilution and poor financial performance, lead...
2023-08-15 13:14:27 ET Gainers: Delcath Systems ( DCTH ) +96% . Sacks Parente Golf ( SPGC ) +95% . Novo Integrated Sciences ( NVOS ) +61% . T2 Biosystems ( TTOO ) +45% . Siyata Mobile ( SYTA ) +36% . Grove Collaborative Holdi...
Delcath Systems, Inc. (NASDAQ: DCTH) is one today's most active stocks by volume. So far today, approximately 75.98M shares of Delcath Systems, Inc. have been exchanged, as compared to an average 30-day volume of 65,969 shares. Delcath Systems, Inc., an interventional oncology company, focuses...
2023-08-15 10:17:36 ET Gainers: Delcath Systems ( DCTH ) +90% . Pharvaris ( PHVS ) +22% . ENDRA Life Sciences ( NDRA ) +14% . NeurAxis ( NRXS ) +12% . SomaLogic ( SLGC ) +12% . Losers: Design Therapeutics ( DSGN ) -6...
2023-08-15 06:48:41 ET More on Delcath Delcath Systems: HEPZATO KIT Should Receive Approval On Aug 14 PDUFA Delcath Systems Is Prepared For A U.S. Commercial Launch Delcath wins FDA review for cancer drug device Delcath Systems announces up to $85M financing ...
Delcath Systems, Inc. Announces FDA Approval of HEPZATO KIT™ for the Treatment of Adult Patients with Unresectable Hepatic-Dominant Metastatic Uveal Melanoma PR Newswire HEPZATO KIT is the only FDA approved liver-directed therapy to treat metastatic uveal melanoma ...
2023-08-11 07:00:00 ET Summary Delcath Systems recently passed FDA inspection without any manufacturing-related observations. The medical review for HEPZATO KIT has likely concluded successfully; FDA seems to have proposed a Black Box Warning, instead of asking for more clinical d...
2023-08-09 17:39:32 ET Delcath Systems press release ( NASDAQ: DCTH ): Q2 GAAP EPS of -$0.58 beats by $0.02 . Revenue of $0.5M (-37.5% Y/Y) misses by $0.24M . Shares -1.29% AH. For further details see: Delcath Systems GAAP EPS of -$0.58 beats by $...
Delcath Systems Reports Second Quarter 2023 Results and Provides Business Update PR Newswire NEW YORK , Aug. 9, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of ...
News, Short Squeeze, Breakout and More Instantly...
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on August 5, 2024, at 4:30 PM Eastern Time to discuss results for its second quarter ended June 30, 2024...
2024-07-16 23:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-17 07:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...